Highlights

  • PainChek shares surged 20% on 14 April 2026 following a major commercial update.
  • Agreement signed with Sabra Health Care REIT to support deployment across up to 20,000 beds.
  • Sabra operates 329 facilities across the United States and Canada.
  • Pricing set between USD $55–$75 per bed annually.
  • Sabra to fund PainChek adoption on behalf of operators, reducing barriers to entry.
  • Model expected to be scalable across other North American REITs.
  • Initial rollout underway with five operators, with more in the pipeline

PainChek Ltd (ASX:PCK) shares surged 20% to AUD 0.18 on 14 April 2026, with the sharp move higher following the release of a significant commercial update tied to its North American expansion strategy. Despite the strong single-day gain, the stock remains down 45.45% over the past year, highlighting the importance of this latest development in shaping investor sentiment.

The upward momentum comes after the company announced a Master Services Agreement with Sabra Health Care REIT, Inc., a major North American healthcare real estate investment trust, marking a key milestone in PainChek’s efforts to scale its presence across the region.

Company Overview and Technology Platform

PainChek Ltd is a healthcare technology company focused on digital pain assessment and monitoring solutions. Its core product, the PainChek application, is described as the world’s first regulatory-cleared medical device designed to assess pain using artificial intelligence.

The platform integrates automated facial recognition analysis with traditional pain scoring systems, enabling consistent and objective pain assessment. It is particularly suited for individuals who are unable to reliably self-report pain, including those living with dementia or other cognitive impairments.

PainChek is available on smartphones and tablets and combines AI-driven analytics with clinical reporting tools, allowing healthcare providers to monitor, document, and manage pain more effectively at the point of care.

The solution has received regulatory clearance across multiple jurisdictions, including Australia, the United States, Canada, the European Union, the United Kingdom, and several Asia-Pacific markets. To date, the platform has been deployed across more than 2,000 aged care facilities globally and has supported over 18 million digital pain assessments.

Landmark Agreement Unlocks North America Opportunity

The agreement with Sabra Health Care REIT represents a major commercial milestone for PainChek, providing a pathway for deployment across up to 20,000 beds within Sabra’s network of 329 facilities spanning the United States and Canada.

Sabra, with an approximate market capitalisation of USD $5 billion, owns and invests in a wide range of healthcare and senior care properties, including skilled nursing facilities, long-term care centres, and senior housing communities.

Under the terms of the agreement, Sabra will fund the implementation of PainChek’s solution on behalf of its operating partners. This structure is designed to significantly reduce financial barriers for individual facility operators, enabling broader and faster adoption across the portfolio.

The pricing framework for the solution ranges between USD $55 and $75 per bed per annum. The lower end of the pricing range applies to customers entering longer-term agreements of two to three years or those participating in collaborative research or outcomes-based projects with PainChek.

The agreement is structured as a perpetual arrangement, with either party having the option to terminate after the initial 12-month period, subject to 90 days’ notice.

Owner-Led Model Aims to Accelerate Adoption

A key feature of the agreement is Sabra’s commitment to introduce PainChek to all current and future operators within its network. This owner-led endorsement is expected to streamline the sales process by reducing the need for individual negotiations at the facility level.

By funding the solution centrally, Sabra effectively removes a key adoption barrier, enabling PainChek to pursue widespread implementation without a corresponding increase in sales and marketing expenditure.

This model represents a shift from traditional healthcare technology sales approaches, where adoption is often driven at the operator level. Instead, the agreement positions the property owner as the primary driver of technology deployment across its portfolio.

PainChek has indicated that this structure creates a repeatable and capital-efficient pathway to scale, particularly within large institutional networks.

Initial Rollout and Expansion Pipeline

The rollout of PainChek across Sabra’s network is expected to occur in stages. The company is currently in the process of finalising agreements with an initial group of five operators, with a further ten operators already identified as part of the near-term pipeline.

This phased approach reflects the scale of the network and allows for progressive implementation across multiple facilities.

The staged deployment is also expected to provide operational insights that can support broader rollout efforts, as well as potential participation in collaborative research initiatives tied to long-term agreements.

Replicable Model Across Healthcare REITs

PainChek has highlighted that the agreement with Sabra is not only significant in its own right but also serves as a template for future partnerships.

The company believes the owner-funded deployment model can be replicated across other healthcare real estate investment trusts and institutional asset owners in North America, many of which control large portfolios of aged care and senior living facilities.

This approach aligns with PainChek’s broader strategy of scaling efficiently in the region by leveraging institutional relationships rather than relying solely on individual facility adoption.

By targeting asset owners with extensive networks, the company aims to achieve broader market penetration with lower incremental costs.

Clinical Utility and Market Positioning

PainChek is designed to improve the consistency and accuracy of pain assessment, particularly in populations where communication challenges can hinder traditional evaluation methods.

The platform reduces subjectivity by automating key components of the assessment process, helping to minimise variability between different carers or clinicians.

It also streamlines workflows by integrating pain scoring, trend analysis, and documentation into a single system, supporting compliance and facilitating communication with healthcare professionals.

Clinical studies conducted in residential aged care settings in Australia and the United Kingdom have been published in peer-reviewed journals, supporting the validity and reliability of the tool in assessing pain in individuals with moderate-to-severe dementia.

The technology has also been extended into adjacent applications, including an infant-focused version capable of identifying facial indicators of pain in young children.

In addition to residential care, the company is expanding into home care settings through partnerships with service providers, reflecting broader demand for remote and technology-enabled healthcare solutions.

What This Means for Investors?

The agreement with Sabra represents a significant step in PainChek’s North American growth strategy, particularly following its regulatory clearance in the United States in 2025.

By securing a partnership with a large, established healthcare REIT, the company has gained access to a substantial network of facilities and potential users.

The funding model embedded in the agreement reduces adoption friction and supports a more scalable deployment approach, which may enhance the company’s ability to expand without proportionally increasing costs.

The pricing structure provides visibility into potential revenue generation on a per-bed basis, while the staged rollout and operator pipeline indicate ongoing implementation activity.

The share price reaction on 14 April 2026 suggests that the market is responding to the scale and structure of the agreement, particularly given its potential to be replicated across other institutional networks.